Core Insights - Renovaro Inc. has entered into a binding Letter of Intent (LOI) to acquire Predictive Oncology in an all-stock transaction, which will enhance its capabilities in cancer diagnostics and therapeutics powered by artificial intelligence [1][2] Short-Term Synergies - The acquisition will provide Renovaro access to Predictive Oncology's biobank of over 150,000 tumor specimens and 200,000 pathology slides, which will accelerate biomarker discovery and clinical trial optimization [5] - Renovaro plans to launch a decision support platform for medical oncologists in 2025, leveraging Predictive Oncology's AI/ML platform that predicts tumor-drug response with 92% accuracy [2][5] Long-Term Vision - The combined organization aims to create a comprehensive solution for cancer patients, integrating diagnostics, early detection, personalized therapies, and biomarker discovery [5] - The partnership is expected to streamline the development and rollout of new diagnostic tests in Europe, enhancing speed to market and expanding global reach [5] - The collaboration will enable the introduction of novel assays for predicting patient response to chemotherapy in European markets [5] Transaction Details - Renovaro will acquire 100% of Predictive Oncology's common shares through the issuance of preferred stock [7] Company Background - Predictive Oncology specializes in using AI and machine learning for early biomarker and drug discovery, with a scientifically validated platform that predicts tumor response to drugs [8] - Renovaro focuses on accelerating precision and personalized medicine through AI and biotechnology platforms for early diagnosis and targeted treatments [9]
Renovaro to Acquire Predictive Oncology in All-Stock Transaction